{
  "abstract": "Background : Recommended treatment after acute coronary syndrome (ACS) involves high-intensity statin therapy to achieve the low-density lipoprotein (LDL-C) target of<1.4mmol/L (European guidelines), but many patients discontinue statins because of real or perceived side-effects. Whether body mass index (BMI) influences statin intolerance remains unclear. Aim : To assess statin tolerance 3months after initiation, and to identify factors determining tolerance and persistence. Methods : STATIC was a single-centre cohort study (November 2021 to April 2023) of patients admitted to cardiac intensive care units for ACS. The study had three stages: T0 (admission) ; W6 (6 weeks after ACS: statin efficiency); and M3 (3months after ACS: statin tolerance and persistence). SAMS score was used to evaluate imputability in patients reporting muscular side-effects. Multivariable analysis identified factors influencing tolerance; statin persistence was assessed using pharmacy dispensing data. Results : Overall, 289 patients were included (77.9% men; mean age 64.2years; 22.7% with BMI≥30kg/m2). At T0, 38.1% had hypertension, 28.5% dyslipidaemia and 15.9% diabetes. At discharge, 269 patients received statins: 97.0% had a high-intensity statin; 43.5% had a statin/ezetimibe combination. At W6, mean LDL-C was 1.58mmol/L, with 45.5% at the LDL-C target. At M3, 6.0% reported side-effects (3.6% muscular, 1.2% liver, 1.2% gastrointestinal). Mean SAMS score was 5.67. No significant differences in muscular or hepatic side-effects were found between patients with BMI≥30 versus<30 kg/m2. Persistence was 98.4% at M3 follow-up. The proportion of patients on a high-intensity statin or a statin/ezetimibe did not change from discharge to M3 (P=0.45 and P=1.00, respectively). Conclusions : Statins are effective, but not always enough to reach LDL-C target. Tolerance and persistence were good, with muscular side-effects as expected, but without any guarantee of statin imputability. BMI did not influence statin tolerance in this study.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": null,
  "arxiv": null,
  "author_total": 11,
  "authors": [
    {
      "name": "Morgane Brobst"
    },
    {
      "name": "Nicolas Chapet"
    },
    {
      "name": "Daylale Benchalkha"
    },
    {
      "name": "Elise Bourgeois"
    },
    {
      "name": "Fanchon Herman"
    },
    {
      "name": "Nicolas Molinari"
    },
    {
      "name": "Florence Leclercq"
    },
    {
      "name": "Jean Luc Pasquié"
    },
    {
      "name": "Cyril Breuker"
    },
    {
      "name": "Ariane Sultan"
    },
    {
      "name": "François Roubille"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/acfs5x86zna5w.bib",
  "cited_by": 2,
  "doi": "10.1016/j.acvd.2024.10.332",
  "fulltext_url": null,
  "id": "acfs5x86zna5w",
  "issns": [
    "1875-2136",
    "1875-2128"
  ],
  "landing_url": "https://hal.science/hal-04838759v2",
  "language": "en",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "hal",
      "0.sdv"
    ],
    [
      "hal",
      "1.sdv.mhep"
    ],
    [
      "hal",
      "1.sdv.sp"
    ],
    [
      "hal",
      "1.sdv.spee"
    ],
    [
      "hal",
      "2.sdv.mhep.csc"
    ],
    [
      "hal",
      "2.sdv.mhep.em"
    ],
    [
      "hal",
      "2.sdv.sp.pharma"
    ],
    [
      "openalex",
      "2746|Lipoproteins and Cardiovascular Health"
    ]
  ],
  "openalex": "W4405236593",
  "pdf_url": "https://hal.science/hal-04838759/document",
  "pmcid": null,
  "pmid": "39732563",
  "published": "2026-09-01",
  "publisher": "Elsevier ; Société française de cardiologie [2008-....]",
  "ris": "https://research.draconitic.com/paper/acfs5x86zna5w.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:17:24Z",
      "native_id": "hal-04838759",
      "source": "hal",
      "url": "https://hal.science/hal-04838759v2"
    }
  ],
  "subjects": [
    {
      "field": "biology",
      "origin": "hal:0.sdv",
      "subfield": "general"
    },
    {
      "field": "medicine",
      "origin": "hal:2.sdv.mhep.csc",
      "subfield": "cardiovascular"
    },
    {
      "field": "medicine",
      "origin": "hal:2.sdv.mhep.em",
      "subfield": "endocrinology-metabolism"
    },
    {
      "field": "medicine",
      "origin": "hal:1.sdv.spee",
      "subfield": "epidemiology-public-health"
    },
    {
      "field": "medicine",
      "origin": "hal:1.sdv.sp",
      "subfield": "pharmacology-toxicology"
    }
  ],
  "title": "Impact of obesity on tolerance and persistence of statins in patients within 3 months following an acute myocardial infarction: A real-world study",
  "title_text": "Impact of obesity on tolerance and persistence of statins in patients within 3 months following an acute myocardial infarction: A real-world study",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:17:24Z",
  "url": "https://research.draconitic.com/paper/acfs5x86zna5w",
  "venue": "Archives of cardiovascular diseases",
  "versions": []
}